Immunome Inc

-0.57 (-6.71%)
Products, Regulatory

Immunome Provides Update On Investigational New Drug Application For Imm-Bcp-01 For Treatment Of Covid-19

Published: 01/10/2022 23:51 GMT
Immunome Inc (IMNM) - Immunome Provides Update on Investigational New Drug Application for Imm-bcp-01 for the Treatment of Covid-19.
Immunome - Expects to Provide Requested Information Soon and Remains on Track to Generate Top-line Clinical Data for Imm-bcp-01 in First Half of 2022.
Immunome - Reporting of Imm-bcp-01 Activity Against Omicron Variant in Live Virus Testing by an External Laboratory Also Remains on Track for This Month.
Immunome- Got Clinical Hold Letter From FDA Requesting Further Info Related to Preparation, Administration of Imm-bcp-01 Cocktail at Clinical Sites.
Immunome Inc - Has Already Initiated Requisite Work and Expects to Provide Requested Information Quickly.